Summary
Aclacinomycin-A is a new anthracycline antibiotic with a broad spectrum of antitumor activity in animals. Compared to doxorubicin, it was found to produce less cardiotoxicity and alopecia. A Phase I trial of aclacinomycin-A given as a weekly 15 min IV infusion was conducted in 20 previously treated patients with advanced solid tumors. Four dose levels ranging from 40 to 100 mg/m2 were studied; myelotoxicity was dose-limiting at 85 and 100 mg/m2. Other toxicities were moderate to severe nausea and vomiting in 9 patients, mild phlebitis in 2 patients, and mild abnormality of liver function tests in 3 patients. No cardiac or renal toxicities were seen, but two partial responses were observed. The pharmacokinetic profile of aclacinomycin-A in plasma and urine was studied in 3 patients given 65 mg/m2 using a high performance liquid chromatography assay. The data obtained were consistent with a two compartment model of drug disposition with initial and terminal half-life values of 6.6 min and 13.3 h, respectively. The major fluorescent metabolite was eliminated with a terminal half-life of 25 h. Two metabolites as well as the parent drug were excreted in the urine as less than 10% of the doses given. This pharmacokinetic profile is similar to that of other anthracyclines, although aclacinomycin-A appears to have lower blood levels than doxorubicin given at equivalent doses. On this weekly schedule, the recommended dose is 65 mg/m2 for Phase II trials.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Oki T, Matusuzawa Yl, Yoshimato A, Numata K, Kitamura I, Hori S, Takamatsu A, Umezawa H, Ishizuka M, Naganawa H, Suda H, Haraada M, Takeuchi T: New antitumor antibiotics, aclacinomycin-A and B. J Antibiot (Tokyo) 28:830–834, 1975
Aclacinomycin-A (NSC 208 734). Clinical brochure, NCI, July, 1979
Hori S, Shirai M, Hirano S, Oki T, Inui T, Tsukagoshi S, Ishizuka M, Takeuchi T, Umezawa H: Antitumor activity of new anthracycline antibodies, aclacinomycin-A and its analogs and their toxicity. Gann 68:685–690, 1977
Oki T, Iguchi H, Hori S, Inui T, Takeuchi T, Umezawa H: New anthracycline antibiotic aclacinomycin-A: action and metabolism. Proc 12th Int Cancer Cong 2:21–22, 1978
Mathe G, Bayssas M, Gouveia J, Dantchev D, Ribaud P, Machover D, Misset J, Schwarzenberg L, Jasmin C, Bayat M: Preliminary results of a Phase II trial of aclacinomycin in acute leukemia and lymphosarcoma: An oncostatic anthracycline that is rarely cardiotoxic and induces no alopecia. Cancer Chemother Pharmacol 1:259–262, 1978
Oki T, Takeuchi T, Oka S, Umezawa H: New anthracycline antibiotic aclacinomycin-A: Experimental studies and correlations with clinical trials. Recent Results Cancer Research 76:21–40, 1980
Ogasawara Y, Masuda Y, Goto S, Mori S, Oki T: High performance liquid chromatographic determination of aclacinomycin-A and its related compounds. II. Reverse phase HPLC determination of aclacinomycin-A and its metabolites in biological fluids using fluorescence detection. J Antibiot 34:52–57, 1981
Sedman A, Wagner J: Autoan Manual. J. Wagner, Upjohn Center for Clinical Pharmacology, The University of Michigan Medical Center, Ann Arbor, MI 48109
Furue H, Furkawa K, Nakao I, Harashima S, Yokoyama T, Kanko T, Fujii A: Clinical information of aclacinomycin-A. Cancer Chemother (Japan) 4:75–79, 1977
Benjamin R, Riggs C, Bachur N: Pharmacokinetics and metabolism of adriamycin in man. Clin Pharmacol Ther 14:592–600, 1973
Benjamin R, Riggs C, Bachur N: Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function. Cancer Res 37:1416–1420, 1977
Alberts D, Bachur N, Holtzman J: The pharmacokinetics of daunomycin in man. Clin Pharmacol Ther 12:96–104, 1971
Reich S, Crooke S: Carminomycin in Anthracyclines: Current Status and New Development. S Crooke and S Reich (eds), Academic Press, New York, 1980, pp 295–313
Seyland-Jones B, Deesen P, Wittes R, Young C: High pressure liquid chromatography methodology and human plasma pharmacokinetics of 4′-epi-doxorubicin and its metabolites. Clin Pharmacol Ther 31:244, 1982
Cassinelli G, Grein A, Masi P, Suarato A, Bernardi L, Arcamone F, Di Marco A, Casazza A, Pratesi G, Soranzo C: Preparation and biological evaluation of 4–0-demethyl-daunorubicin (carminomycin I) and of its 13 dihydro derivatives. J Antibiot (Tokyo) 31:178–184, 1978
Meriwether W, Bachur N, Gee M: Inhibition of DNA and RNA metabolism by daunorubicin (D1) and its major metabolite (D2) in L1210 mouse leukemia (abstract) Clin Res 19:491, 1971
Weiss A, Metter G, Fletcher W, Wilson W, Grage T, Ramirez G: Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity. Cancer Treat Rep 60:813–822, 1976
Legha S, Benjamin R, Mackay B, Ewer M, Wallace S, Valdivieso M, Rasmussen S, Blumenschein G, Freireich E: Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Int Med 96:133–139, 1982
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Karanes, C., Young, J.D., Samson, M.K. et al. Phase I trial of aclacinomycin-A. Invest New Drugs 1, 173–179 (1983). https://doi.org/10.1007/BF00172077
Issue Date:
DOI: https://doi.org/10.1007/BF00172077